Although overdose deaths from heroin and prescription opioids have declined, deaths involving synthetic opioids are on the rise. Much of the current wave of overdoses is linked to one synthetic opioid: fentanyl.
About half of all U.S. states now have policies that criminalize substance use during pregnancy, consider it grounds for civil commitment, or consider it child abuse or neglect. But research suggests that punitive policies aren't beneficial for infants or their mothers.
This article proceeds in three parts: discussions of the general goals and role of public health tort litigation, the demonstrated and potential value of opioid litigation to achieve public health goals, and a conclusion.
Prescription opioid use and driving is a public health concern given the risks associated with drugged driving. We examined the prevalence and correlates of driving after taking prescription opioids among adults seeking emergency department treatment.
We used insurance claims to examine the prevalence and prescribing patterns of prescription opioids in a national cohort of individuals experiencing a treated heroin-related overdose between 2010 and 2017.
The existing literature on naloxone access laws in the United States supports beneficial effects for increased naloxone distribution, but provides inconclusive evidence for reduced fatal opioid overdose.
We review the change over time in state-level policy environments around substance use in pregnancy and contrast the policy response with the principles and guidance from professional societies and federal agencies.
A study examined the rates of hospitalisation or death related to severe bacteria infections among people who inject heroin in South London, England. The report compared these rates to the general population and calculated the cost of admissions.
This study found an increase in the rate of overdose after Medicare Part D coverage began to include benzodiazepines among adults aged 65 to 69 years and 80 years or older and an increase in the rate of fall-related injury in adults 80 years or older.
State-level prescription drug monitoring programs that incorporate robust design features can significantly reduce the proportion of commercially insured adults who receive opioid prescriptions as well as the strength of those prescriptions.
In the profitable buprenorphine market, pharmaceutical manufacturer Reckitt Benckiser exploited various Food and Drug Administration regulatory procedures to impede entry of generic competitors and maintain elevated prices.
Early evidence suggests that opioid duration limits had a variable association with postoperative opioid prescribing and should only be part of a larger, multifaceted effort to reduce excessive postoperative opioid prescribing.
In this article, the authors use the case of Suboxone to demonstrate egregious anti-competitive practices that delay generic entry, estimate the costs of these delays to the public, and suggest legislative and regulatory reforms to prevent these practices going forward.